Search
Close this search box.
Search
Close this search box.

The latest trends in US drug development

US drug development

In this blog, Katy Rudnick, Vice President and Head of US Regulatory Affairs at Boyds, explores the latest trends in US drug development and initiatives at the FDA and discusses their potential impact on drug development in 2024.

MHRA announces new pathway for device regulations

The Medicines and Healthcare products Regulatory Agency (MHRA) has published the “MHRA Roadmap towards the future regulatory framework for medical devices”. With the of release of this document on the 9th January 2024, the Agency has provided an update on the intended timelines to implement the future core regulations via a series of new Statutory Instruments.

The importance of diversity in clinical trials

In this article, Dr Harriet Gray-Stephens, Pharmaceutical Physician in the Clinical and Medical Affairs team at Boyds, discusses the importance of diversity in clinical trials and the steps that are being taken to improve the quality of data derived from clinical research.

A guide to plain language summaries (PLS)

Plain Language Summaries

In this blog, Naomi Clout, Senior Regulatory and Medical Writer at Boyds, discusses the importance of Plain Language Summaries as an effective scientific communication tool that can be easily comprehended by people who aren’t experts in the field and the steps involved in creating a PLS.